Receptor tyrosine kinase therapeutic monoclonal antibodies

The therapeutic challenges of receptor tyrosine kinases
SYnAbs generates custom therapeutic monoclonal antibodies to receptor tyrosine kinases (RTKs) thanks to proprietary technologies and unique expertise
Anti-CD25 therapeutic monoclonal antibody strategies
SYnabs unique anti-CD25 anti-IL2R therapeutic antibody has shown great promise in clinical trials. SYnAbs antagonist anti-IL2Ra/Tac depletes Tregs for GvHD and cancer treatments.

IL1RAP, a new biomarker of interest for cancer targeting
SYnAbs unique monoclonal antibodies to IL1RAP